Optimization of the local inhibition of intestinal adenosine deaminase (ADA) by erythro-9-(2-hydroxy-3-nonyl)adenine: Enhanced oral delivery of an ADA-activated prodrug for anti-HIV therapy

Journal of Pharmaceutical Sciences

Volumn 87, Issue 5, 1998, Pages 578-585

  Singhal, Dharmendra ^a,b   Anderson, Bradley D ^a  

^a UNIVERSITY OF UTAH   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 CHLORO 2',3' DIDEOXYPURINE; 9 (2 HYDROXY 3 NONYL)ADENINE; ADENOSINE DEAMINASE INHIBITOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; INTESTINE ENZYME; PENTOSTATIN; PRODRUG; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG PROTEIN BINDING; DRUG TRANSFORMATION; ENZYME BINDING; ENZYME INHIBITION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTESTINE ABSORPTION; INTESTINE PERFUSION; INTRAVENOUS DRUG ADMINISTRATION; LIPOPHILICITY; MALE; NONHUMAN; RAT; STEADY STATE; TARGET ORGAN;

EID: 0031969148     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1021/js970377b     Document Type: Article

References (26)

1. Barchi, J. J., Jr.; Marquez, V. E.; Driscoll, J. S.; Ford, H., Jr.; Mitsuya, H.; Shirasaka, T.; Aoki, S.; Kelley, J. A. Potential anti-AIDS drugs. Lipophilic, adenosine deaminase-activated prodrugs. J. Med. Chem. 1991, 34, 1647-1655.
2. Morgan, M. E.; Chi, S.-C.; Murakami, K.; Mitsuya, H.; Anderson, B. D. Central nervous system targeting of 2′,3′-dideoxyinosine via adenosine deaminase-activated 6-halo-dideoxypurine prodrugs. Antimicrob. Agents Chemother. 1992, 36, 2156-2165.
3. Shirasaka, T.; Watanabe, K.; Yoshioka, H.; Kojima, E.; Aoki, S.; Murakami, K.; Mitsuya, H. Lipophilic 6-halo-2′,3′-dideoxypurine nucleosides: potential antiretroviral agents targeting HIV-associated neurologic disorders. In Advances in Molecular Biology and Targeted Treatment for AIDS; Kumar, A., Ed.; Plenum Press: New York. 1991; pp 323-333.
4. Ford, H., Jr.; Siddiqui, M. A.; Driscoll, J. S.; Marquez, V. E.; Kelley, J. A.; Mitsuya, H.; Shirasaka, T. Lipophilic, acid-stable, adenosine deaminase-activated anti-HIV prodrugs for central nervous system delivery. 2. 6-Halo and 6-alkoxy prodrugs of 2′-β-fluoro-2′,3′-dideoxyinosine. J. Med. Chem. 1995, 38, 1189-1195.
5. Singhal, D.; Morgan, M. E.; Anderson, B. D. Role of brain tissue localized purine metabolizing enzymes in the central nervous system delivery of anti-HIV agents 2′-β-fluoro-2′,3′-dideoxyinosine and 2′-β-fluoro-2′,3′-dideoxyadenosine in rats. Pharm. Res. 1997, 14, 786-792.
6. Driscoll, J. S.; Siddiqui, M. A.; Ford, J., H.; Kelley, J. A.; Roth, J. S.; Mitsuya, H.; Tanaka, M.; Marquez, V. E. Lipophilic, acid-stable, adenosine deaminase-activated anti-HIV prodrugs for central nervous system delivery. 3. 6-Amino prodrugs of 2′-β-fluoro-2′,3′-dideoxyinosine. J. Med. Chem. 1996, 39, 1619-1625.
7. Anderson, B. D.; Galinsky, R. E.; Baker, D. C.; Chi, S.-C.; Hoesterey, B. L.; Morgan, M. E.; Murakami, K.; Mitsuya, H. Approaches toward the optimization of CNS uptake of anti-AIDS agents. J. Controlled Release 1992, 19, 219-230.
8. Anderson, B. D.; Morgan, M. E.; Singhal, D. Enhanced oral bioavailability of ddI after administration of 6-CI-ddP, an adenosine deaminase-activated prodrug, to chronically catheterized rats. Pharm. Res. 1995, 12, 1126-1133.
9. Singhal, D.; Ho, N. F.; Anderson, B. D. Absorption and intestinal metabolism of purine dideoxynucleosides and an adenosine deaminase-activated prodrug of 2′,3′-dideoxyinosine in the mesenteric vein cannulated rat ileum. J. Pharm. Sci. 1998, 87, 569-577 (preceding paper in this issue).
10. Tifton, K. F. Kinetics and enzyme inhbition studies. In Enzyme Inhibitors as Drugs; Sandler, M., Ed.; University Park: Baltimore, 1980; pp 1-23.
11. Ho, N. F.; Park, J. Y.; Ni, P. F.; Higuchi, W. I. Advancing quantitative and mechanistic approaches in interfacing gastrointestinal drug absorption studies in animals and humans. In Animal Models for Oral Drug Delivery in Man: In Situ and In Vivo Approaches; Crouthamel, W., Sarapu, A. C., Eds.; APhA: Washington, DC, 1983; pp 27-106.
12. Komiya, I.; Park, J. Y.; Kamani, A.; Ho, N. F. H.; Higuchi, W. I. Quantitative mechanistic studies in simultaneous fluid flow and intestinal absorption using steroids as model solutes. Int. J. Pharm. 1980, 4, 249-262.
13. Ho, N. F. H. Biophysical kinetic modeling of buccal absorption. Adv. Drug Delivery Rev. 1993, 12, 61-97.
14. Agarwal, R. P.; Spector, T.; Parks, J., R. E. Tight binding inhibitors-IV: Inhibition of adenosine deaminase by various inhibitors. Biochem. Pharmacol. 1977, 26, 359-367.
15. Cristalli, G.; Eleuteri, A.; Volpini, R.; Vittori, S.; Camaioni, E.; Lupidi, G. Adenosine deaminase inhibitors: Synthesis and structure-activity relationships of 2-hydroxy-3-nonyl derivatives of azoles. J. Med. Chem. 1994, 37, 201-205.
16. Antonini, I.; Cristalli, G.; Franchetti, P.; Grifantini, M.; Martelli, S.; Lupidi, G.; Riva, F. Adenosine deaminase inhibitors: Synthesis of deaza analogues of erythro-9-(2-hydroxy-3-nonyl)-adenine. J. Med. Chem. 1984, 27, 274-278.
17. Brogden, R. N.; Sorkin, E. M. Pentostatin: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in lymphoproliferative disorders. Drugs 1993, 46, 652-677.
18. Klohs, W. D.; Kraker, A. J. Pentostatin: future directions. Pharmacol. Rev. 1992, 44, 459-477.
19. Padua, R.; Geiger, J. D.; Dambock, S.; Nagy, J. I. 2′-Deoxycoformycin inhibition of adenosine deaminase in rat brain: In vivo and in vitro analysis of specificity, potency, and enzyme recovery. J. Neurochem. 1990, 54, 1169-1178.
20. 3H]deoxycoformycin ligand binding. J. Neurochem. 1992, 58, 421-429.
21. Plunkett, W.; Alexander, L.; Chubb, S.; Loo, T. L. Comparison of the activity of 2′-deoxycoformycin and erythro-9-(2-hydroxy-3-nonyl)adenine in vivo. Biochem. Pharmacol. 1979, 28, 201-206.
22. McConnell, W. R.; Furner, R. L.; Hill, D. L. Pharmacokinetics of 2′-deoxycoformycin in normal and L1210 leukemic mice. Drug Metab. Dispos. 1979, 7, 11-13.
23. Geiger, J. D.; Lewis, J. L.; MacIntyre, C. J.; Nagy, J. I. Pharmacokinetics of 2′-deoxycoformycin, an inhibitor of adenosine deaminase in the rat. Neuropharmacology 1987, 26, 1383-1387.
24. Brady, T. G.; O'Donovan, C. I. A study of the tissue distribution of adenosine deaminase in six mammal species. Comp. Biochem. Physiol. 1965, 14, 101-120.
25. Chinsky, J. M.; Ramamurthy, V.; Fanslow, W. C.; Ingolia, D. E.; Blackburn, M. R.; Shaffer, K. T.; Higley, H. R.; Trentin, J. J.; Rudolph, F. B.; Knudsen, T. B.; Kellems, R. E. Developmental expression of adenosine deaminase in the upper alimentary tract of mice. Differentiation 1990, 42, 172-183.
26. Mohamedali, K. A.; Guicherit, O. M.; Kellems, R. E.; Rudolph, F. B. The highest levels of purine catabolic enzymes in mice are present in the proximal small intestine. J. Biol. Chem. 1993, 268, 23728-23733.